

## Literatur für onkologie heute 01/2021

### SCHWERPUNKT: CHRONISCHE LEUKÄMIEN

#### Chronische Neutrophilen-Leukämie (S. 17–20)

*P. E. Petrides*

1. Touhy E. A case of splenomegaly with polymorphonuclear neutrophil hyperleukocytosis. *Amer J Med* 1920; 160: 18–25
2. You W, Weisbrot IM. Chronic neutrophilic leukemia. Report of two cases and review of the literature. *J Clin Pathol* 1979; 72: 233–242
3. Sponza E, Virgolini L, Tosato F, Paladini G. Chronic neutrophilic leukemia: report of a case. *Haematologica* 1986; 71: 143–145
4. Hossfeld DK, Lokhorst HW, Garbrecht M. Neutrophilic leukemia accompanied by hemorrhagic diathesis: report of two cases. *Blut* 1987; 54: 109–13
5. Böhm J, Schäfer HE. Chronic neutrophilic leukemia: 14 new cases of an uncommon myeloproliferative disease. *J Clin Pathol* 2002; 55: 862–64
6. Szuber N et al. CSF3R-mutated chronic neutrophilic leukemia: long-term outcome in 19 consecutive patients and risk model for survival. *Blood Cancer J* 2018; 8: 21–25
7. Plo I et al. An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. *J Exp Med* 2009; 206: 1701–7
8. Xia, J et al. Somatic mutations and clonal hematopoiesis in congenital neutropenia. *Blood* 2018; 131: 408–16
9. Maxson JE et al. Oncogenic CSF3R Mutations in chronic neutrophilic Leukemia and atypical CML. *N Engl J Med* 2013; 368: 1781–90
10. Arber DA et al. The 2016 revision to the WHO classification of myeloid neoplasms and acute leukemia. *Blood* 2016; 127: 2391–405
11. Meggendorfer M et al. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia and chronic myelomonocytic leukemia. *Haematologica* 2014; 99: 244–46
12. Zhang QG, Wang J, Gong W-Y, Jin Q-C. Clonal evolution in a chronic neutrophilic leukemia patient. *Hematol* 2019; 24: 455–58
13. Zhang H et al. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. *Blood* 2019; 134: 867–79
14. Matzdorff A et al.. Chronic neutrophilic leukemia – Stem cell transplantation in a very young patient. *Blood* 2020; 136( SUPPL 1): 29
15. Dao KH et al. Significant clinical response to Jak1/2 inhibition in a patient with CSF3-T618I-positive atypical chronic myeloid leukemia. *Leuk Res Rep* 2014; 3: 67–9
16. Hinze A, Rinke J, Hochhaus A, Ernst T. Durable remission with ruxolitinib in a chronic neutrophil leukemia patient harboring a truncation and a membrane proximal CSF3R compound mutation. *Ann Hematol* 2020 Jun 23. doi: 10.1007/s00277-020-04152-w. Online ahead of print
17. Dao, KHT et al. Efficacy of Ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia. *J Clin Oncol* 2020; 38: 1006–18
18. <http://www.orpha.net/data/prj/DE/ID88416DE.pdf>
19. Szuber N, Elliott M, Tefferi A. Chronic neutrophilic Leukemia: 2020 update on diagnosis, molecular genetics, prognosis and management. *Am J Hematol* 2020; 95: 221–24

## **Maligne Lymphome im Kindes- und Jugendalter: Herausforderungen trotz exzellenter Therapieergebnisse (S. 21–31)**

*A. Attarbaschi und G. Mann*

1. Lennert K. Morphology and classification of malignant lymphomas and so-called reticuloses. *Acta Neuropathol Suppl* 1975; Suppl 6: 1–16
2. Swerdlow SH et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood* 2016; 127: 2375–90
3. Burkhardt B et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. *Br J Haematol* 2005; 131: 39–49
4. Attarbaschi A et al. Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents. *Haematologica* 2016; 101: 1581–191
5. Attarbaschi A et al. Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a „Watch and wait“ strategy after complete resection. *Ann Hematol* 2013; 92: 1537–41
6. Mellgren K et al. Non-anaplastic peripheral T cell lymphoma in children and adolescents—an international review of 143 cases. *Ann Hematol* 2016; 95: 1295–305
7. Ronceray L et al. Children and adolescents with marginal zone lymphoma have an excellent prognosis with limited chemotherapy or a watch-and wait strategy after complete resection. *Pediatr Blood Cancer* 2018; 65
8. Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin „s lymphomas: dissimilarities from lymphomas in adults. *Semin Oncol* 1980; 7: 332–39
9. Rosolen A et al. Revised International Pediatric Non-Hodgkin Lymphoma Staging System. *J Clin Oncol* 2015; 33: 2112–18
10. Burkhardt B. Paediatric lymphoblastic T-cell leukaemia and lymphoma: one or two diseases? *Br J Haematol* 2010; 149: 653–68
11. Mauz-Korholz C et al. Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group. *Klin Padiatr* 2015; 227: 314–21
12. Minard-Colin V et al. Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead. *J Clin Oncol* 2015; 33: 2963–74
13. Reiter A et al. Intensive ALL-type therapy without local radiotherapy provides a 90 % event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. *Blood* 2000; 95: 416–21
14. Burkhardt B et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system negative stage III or IV lymphoblastic lymphoma. *J Clin Oncol* 2006; 24: 491–99
15. Landmann E et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. *Haematologica* 2017; 102: 2086–96
16. Burkhardt B, Mueller S, Khanam T, Perkins SL. Current status and future directions of T-lymphoblastic lymphomas in children and adolescents. *Br J Haematol* 2016; 173: 545–59
17. Reiter A et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. *Blood* 1999; 94: 3294–306

18. Woessmann W et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B cell neoplasms: a report of the BFM Group Study NHL-BFM95. *Blood* 2005; 105: 948–58
19. Reiter A et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. *J Clin Oncol* 1994; 12: 899–908
20. Le Deley MC et al. Prognostic factors in childhood anaplastic large cell lymphoma: results of a large European intergroup study. *Blood* 2008; 111: 1560–66
21. Le Deley MC et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. *J Clin Oncol* 2010; 28: 3987–93
22. Mauz-Korholz C et al. Procarbazine free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. *J Clin Oncol* 2010; 28: 3680–86
23. Kurch L et al. The Euro Net paediatric hodgkin network –modern imaging data management for real time central review in multicentre trials. *Klein Padiatr* 2013; 225: 357–61
24. Mauz-Korholz C et al. Pediatric Hodgkin Lymphoma. *J Clin Oncol* 2015; 33: 2975–85
25. Atra A et al. Outcome of relapsed or refractory childhood B-cell acute lymphoblastic leukaemia and B-cell non-Hodgkin's lymphoma treated with the UKCCSG 9003/9002 protocols. *Br J Haematol* 2001; 112: 965–68
26. Burkhardt B et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. *J Clin Oncol* 2009; 27: 3363–69
27. Mosse YP et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. *Lancet Oncol* 2013; 14: 472–80
28. Meinhardt A et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. *J Clin Oncol* 2010; 28: 3115–21
29. Minard-Colin V et al. Results of the randomized Intergroup trial Inter-BNHL Ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): Evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. *J Clin Oncol* 2016; 34 (Suppl 15): 10507–7
30. Metzger ML, Mauz-Korholz C. Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma. *Br J Haematol* 2019; 185: 1142–57
31. Locatelli F et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. *Lancet Haematol* 2018; 5: e450–e461